Effects of Biologics on Vascular Function and Atherosclerosis Associated with Rheumatoid Arthritis
|
|
- Gilbert Bryan
- 8 years ago
- Views:
Transcription
1 CONTEMPORARY CHALLENGES IN AUTOIMMUNITY Effects of Biologics on Vascular Function and Atherosclerosis Associated with Rheumatoid Arthritis György Kerekes, a Pál Soltész, a Henriett Dér, a Katalin Veres, a Zoltán Szabó, b Anikó Végvári, b Yehuda Shoenfeld, c and Zoltán Szekanecz b a Cardiovascular Unit, Third Department of Medicine, and b Department of Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary c Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA). Sustained inflammation is a major risk factor. Apart from traditional vasculoprotective agents, biologics may also exert favorable effects on the vasculature. Indeed, tumor necrosis factor-α (TNF-α) inhibitors agents may transiently improve endothelial function. There are conflicting data regarding the effects of biologics on atherosclerosis and arterial stiffness. Infliximab stimulates the number and differentiation of endothelial progenitor cells that lead to vascular repair. There may be differences in the effects of TNF blockers on dyslipidemia, as long-term infliximab therapy may be proatherogenic, while some studies suggest that etanercept and adalimumab may exert beneficial effects on lipids. TNF blockers may decrease the incidence of cardiovascular events in RA. Preliminary data suggest that rituximab may also improve endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologics on the vasculature. Key words: rheumatoid arthritis; endothelial dysfunction; atherosclerosis; flowmediated vasodilatation; carotid intima-media thickness; arterial stiffness; lipid profile Introduction Accelerated atherosclerosis and increased cardiovascular risk have become major factors of mortality in rheumatoid arthritis (RA). 1 4 Both classical (Framingham) as well as inflammation-associated risk factors have been implicated in atherosclerosis associated with RA, as well as other rheumatic diseases. 2 5 Regarding traditional risk factors, cigarette smoking and dyslipidemia have been implicated in Address for correspondence: Zoltán Szekanecz, MD, PhD, Institute of Medicine, Department of Rheumatology, University of Debrecen Medical and Health Science Center, Hungary Móricz Zs krt. 22., H-4032 Debrecen, Hungary. szekanecz@iiibel.dote.hu the development of atherosclerosis in RA. 2,3 However, there is no clear evidence that obesity, hypertension, diabetes mellitus, or physical inactivity would be crucial in this respect. 2,3 Data on dyslipidemia in RA are also conflicting, and decreased high-density lipoprotein cholesterol (HDL-C) and increased low-density lipoprotein cholesterol (LDL-C) levels may be secondary to chronic inflammation. 2,3 Therefore, RA-associated atherosclerosis cannot be fully explained by Framingham risk factors (Table 1). Thus, inflammatory mechanisms underlying RA are crucial for early atherosclerosis and CVD development. 6,7 Homocysteine and C reactive protein (CRP) are independent risk Contemporary Challenges in Autoimmunity: Ann. N.Y. Acad. Sci. 1173: (2009). doi: /j x c 2009 New York Academy of Sciences. 814
2 Kerekes et al.: Vascular Effects of Biologics in RA 815 TABLE 1. Common Pathogenic Factors in RA and Atherosclerosis 1. Traditional - age - smoking - dyslipidemia, oxldl - sedentary lifestyle immobilization 2. Inflammatory - acute phase proteins (CRP, fibrinogen) - autoantibodies (anti-ccp, RF, anti-oxldl, angti-hsp) - proatherogenic cytokines and chemokines - matrix-degrading metalloproteinases - increased cell adhesion molecule expression - hyperhomocysteinemia - defective apoptosis 3. Iatrogenic - methotrexate bimodal? - corticosteroids bimodal? factors for atherosclerosis. 1 3 Atherosclerotic plaques, as well as the RA joint, contain inflammatory leukocytes mainly T cells, proinflammatory cytokines, chemokines and matrix-degrading enzymes. 1 3,8,9 Endothelial activation, dysfunction, and atherogenesis have been associated with the increased expression of endothelial adhesion molecules. 10 It has been shown that sustained inflammatory activity may be the predominant risk factor for accelerated atherosclerosis and excess CVD mortality in RA. 1 4,8 Accelerated atherosclerosis indicated by increased common carotid intimal-medial thickness (ccimt) has been described in RA. 1 4 As previously reported by us and others, early endothelial dysfunction indicated by impaired flow-mediated vasodilatation (FMD) of the brachial artery precedes atherosclerosis in RA. 1 4,11 In addition, increased arterial stiffness indicated by increased pulse-wave velocity (PWV) and auigmentation index (AIx) has also been associated with RA The detection of early endothelial dysfunction, arterial stiffness and overt atherosclerosis is crucial for the early prevention and management of arthritisrelated vascular disease. Endothelial progenitor cells (EPCs) form a population of blood stem cells that are involved in tissue development, vascular repair, and atherosclerosis Under normal conditions, EPCs become mobilized from the bone marrow and differentiate into mature endothelial cells. 15,16 Attenuated vasculogenesis and vascular repair have been associated with vascular diseases, as well as with RA Defective vascular repair and low circulating EPC numbers were correlated with disease activity. 14 Furthermore, TNF-α inhibits the colony formation of EPCs. 14 After finding arthritis patients at high risk for vascular diseases, optimal prevention and management are needed in order to minimize vascular complications and decrease cardio- and cerebrovascular mortality. Until recently, there have been no official recommendations in this respect. Certainly, vasoprotective therapy, including aspirin, statins, folate, or vitamin B12, should be introduced to RA patients at a higher vascular risk. 2 4 Yet the effective control of systemic inflammation maybe even more important. Corticosteroids and methotrexate (MTX) may have bidirectional effects, as on one hand the use of these agents may be beneficial by controlling autoimmune inflammation, while on the other hand, corticosteroids and MTX themselves may be proatherogenic. 2 4 Recently, the European League Against Rheumatism (EULAR) has set up a task force that has prepared nine recommendations for cardiovascular risk management in arthritis. Apart from other recommendations, the EU- LAR task force suggests that adequate control of disease activity is necessary to lower the CVD risk (best evidence for anti-tnf treatment and MTX treatment). 17 Numerous recent publications have suggested that biologic agents, primarily tumor necrosis factor-α (TNF-α) inhibitors, may have significant effects on the vasculature. 10,18 40 For example, there have been several reports primarily on infliximab, but also on adalimumab and etanercept suggesting that these biologics may influence the lipid profile,
3 816 Annals of the New York Academy of Sciences endothelial dysfunction, carotid atherosclerosis, arterial stiffness, and probably CVD outcome in RA In addition, two recent studies indicated similar beneficial effects of rituximab. 18,19 In this review, we summarize recent, sometimes controversial data on the effects of various biologic agents on metabolic changes, atherosclerosis and CVD associated with RA. Endothelial Dysfunction Numerous recent reports have suggested that anti-tnf biologicals may have effects on the vasculature and lipid profile in RA patients. Some of these reports are controversial. Most data have been published with respect to infliximab. In the first study, published in 2002, FMD was assessed in 11 patients with active RA before and after 12 weeks of infliximab therapy. Infliximab improved endothelium-dependent vasodilation indicated by FMD, but it did not influence endothelium-independent vasodilation. The beneficial effect of infliximab on endothelial function was accompanied by decreased erythrocyte sedimentation rates and CRP levels. 20 In another study, FMD was assessed before and 36 weeks after infliximab therapy in comparison to patients on conventional immunosuppressive treatment. Anti- TNF therapy significantly improved endothelial function in comparison to traditionally treated patients. 21 Only a transient improvement of endothelial function upon infliximab therapy was reported in various studies. In a study of seven RA patients, infliximab treatment resulted in a rapid improvement of FMD in all subjects. However, after a short-term beneficial effect, FMD returned to baseline by 4 weeks after infusion. 22 In 10 patients with severe, long-standing RA, infliximab treatment resulted in a reversible, transient increase in FMD. 23 Infliximab treatment of 34 RA patients resulted in the suppression of soluble endothelial cell adhesion molecule production. 10 Low levels of circulating adiponectin have been associated with endothelial dysfunction. In a study of 15 RA patients, infliximab treatment resulted in a short-term increase of serum adiponectin levels, which was associated with significant improvement of endothelial function. 24 Thus, short courses of infliximab only transiently improved endothelial function in most studies. Therefore, long-term use of anti-tnf biologics may be needed in order to reduce the cardiovascular complications in RA. Regarding other TNF blockers, eight RA patients refractory to infliximab were treated with adalimumab. There was a rapid increase of FMD at day 2 that was sustained for 12 weeks. This was accompanied by decreases of DAS28 and CRP levels. 25 In a recent pilot study on vascular effects of rituximab, we included five RA patients with a mean age of 42 years and a mean disease duration of 5.8 years. We administered two infusions of 1000 mg rituximab each at 2 weeks apart after corticosteroid premedication. We assessed brachial artery FMD at baseline, at week 2 (right before the second rituximab infusion), at week 6 and at week 16. All five patients exerted % of improvement in FMD by week 16, a time long enough to exclude corticosteroid effects. 19 In a very recent report, Gonzalez-Juanatey et al. 18 used the same protocol to treat five consecutive female patients with active RA refractory to TNF blockers with two infusions of 1000 mg rituximab each. FMD was assessed at baseline, at week 2 and at month 6. Rituximab treatment resulted in dramatic increases of FMD at week 2 and at month 6. Improvement of endothelial function was associated with decreases in CRP levels and DAS28 scores. Carotid Atherosclerosis Regarding carotid atherosclerosis, ccimt was assessed in 30 patients before infliximab or etanercept therapy and 12 months after therapy. A significant improvement in ccimt on both sides was observed, which was preceded
4 Kerekes et al.: Vascular Effects of Biologics in RA 817 by an early and lasting decrease in disease activity markers. 26 In contrast, 56-week infliximab treatment of 26 RA patients did not affect ccimt. 27 Thus, data are rather conflicting regarding the effects of TNF blockers on carotid atherosclerosis. In our rituximab study described above, despite of the short follow-up time of 16 weeks, carotid atherosclerosis significantly improved in three of five patients by the end of the observation period. 19 There have been no other reports on the effects of rituximab on overt atherosclerosis in RA. Arterial Stiffness Aortic stiffness was assessed in nine RA patients treated with etanercept at 0, 4, and 12 weeks. Anti-TNF therapy significantly reduced aortic PWV by weeks 4 and In a long-term cohort, 26 RA patients were treated with infliximab for one year. In this study, 56- week infliximab treatment resulted in a significant decrease of PWV. 27 In contrast, when 14 RA patients were treated with either infliximab, etanercept, or adalimumab, despite significant clinical response and reduction of inflammation, there was no change in arterial stiffness indicated by AIx. 28 Thus, results on arterial stiffness are rather controversial. However, different TNF blockers were used in the studies. In addition, some investigators assessed PWV, while others measured AIx. Therefore, data from different studies may not be comparable. Lipid Profile and Insulin Resistance Regarding lipid profiles, short-term infliximab treatment of 69 RA patients resulted in significant increases in both total cholesterol and HDL-cholesterol levels, which was not accompanied by a favorable effect on the atherogenic index. 29 Similar results were obtained from another study that included 34 consecutive RA patients treated with infliximab, etanercept, or adalimumab. Anti-TNF treatment resulted in significant increases in both total cholesterol and HDL-C levels, but no changes in the atherogenic index were observed. 30 In a study of 19 patients with active RA, infliximab treatment increased total cholesterol, HDL-C, LDL-C, and triglyceride levels, while the atherogenic index and the LDL-C/HDL- C ratio remained unchanged. 31 Thus, for most studies, even if infliximab altered the lipid profile, there was no change in the atherogenic index. Some other studies yielded negative results. In a study of 82 RA and ankylosing spondylitis patients, infliximab treatment exerted a neutral effect on the lipid profile since neither LDLcholesterol levels nor total cholesterol/hdl-c and triglyceride/hdl-c ratios changed during a 6-month course of treatment. 32 Others also did not observe any effects of infliximab, etanercept or adalimumab on the lipid profile including total cholesterol, triglyceride, HDL- C or LDL-C levels in 29 RA patients. 33 In one report, infliximab treatment of 32 patients with refractory RA resulted in the induction of very high VLDL-triglyceride levels. 34 Although this result has not been confirmed by larger studies, RA patients treated with infliximab may need careful serum triglyceride level monitoring. After these short-term studies, 55 RA patients were treated with infliximab and followed for 6 months, while 31 of these patients were treated and followed for one year. The shortterm effects of anti-tnf therapy on the lipid profile seemed beneficial; however, plasma concentrations of total cholesterol, LDL-C and the atherogenic index increased after 6 months and up to one year of infliximab therapy. Thus, long-term infliximab treatment may rather be proatherogenic. 35 Regarding other TNF blockers, in a study on 33 RA patients, adalimumab treatment resulted in significantly increased HDL-C levels, while LDL-C and triglyceride levels did not change, 36 suggesting a favorable effect of
5 818 Annals of the New York Academy of Sciences adalimumab on the HDL-C/LDL-C ratio. Adalimumab also reduced the atherogenic index after 12 weeks of treatment in eight RA patients. 25 When 65 consecutive patients with RA and ankylosing spondylitis were treated with infliximab or etanercept, infliximab treatment increased total cholesterol and LDL-C levels but had no effects on HDL-C and triglyceride production, whereas etanercept significantly increased HDL-Cbut had no effects on total cholesterol or LDL-C levels. 37 Although the majority of studies have been performed administering infliximab, data summarized above suggest that various TNF-α blockers may have different effects on the lipid profile and atherogenicity. While longterm infliximab treatment may be proatherogenic, etanercept and adalimumab treatment may be associated with a less atherogenic profile. As one possible explanation of these differences, while etanercept inhibits both TNFα and lymphotoxin-α, infliximab only blocks TNF-α. Indeed, lymphotoxin-α was found to be far more atherogenic than TNF-α.Thus,the blockade of lymphotoxin-α in addition to that of TNF-α by etanercept may account for the anti-atherogenic profile of etanercept in comparison to infliximab. 37 In our study described above, rituximab treatment decreased total cholesterol and increased HDL-C levels in four of five patients, yielding a mean 8.5% decrease in total cholesterol and a mean 35.4% increase in HDL-C by week 16. In contrast, effects on LDL-C and triglyceride levels were rather controversial, as both increases and decreases in LDL- C and triglyceride production were observed even in the same patient during the follow-up period. 19 To date, no other reports are available on the effects of rituximab on lipid profiles in RA. Endothelial Progenitor Cells As described above, there is a deficiency of EPCs in RA, which has been associated with abnormal vascular repair in atherosclerosis As TNF-α suppresses the colony-forming activity of EPCs, 14 anti-tnf treatment may have beneficial effects on EPC number and function. Indeed, infliximab treatment of 14 active RA patients resulted in a 33% increase in circulating EPC numbers. Anti- TNF treatment also improved EPC adhesion and differentiation. The stimulation of EPC number and function by infliximab was correlated with clinical response indicated by DAS28 changes. 38 Clinical Vascular Effects After describing the mechanisms of action of biologics on atherosclerosis, endothelial function, arterial stiffness, lipid profile, and vasculogenesis, it is even more important to know whether these effects will influence the morbidity and mortality of CVD. In a Swedish national register, 531 RA patients received infliximab or etanercept therapy between 1999 and 2005 and the primary end point was the first CVD event. In the anti-tnf treated patients, the age- and sex-adjusted incidence rate of first CVD events was less than half of that observed in the anti-tnf nontreated patients. 39 Recently, data from the British Society for Rheumatology Biologics Register were analyzed and rates of myocardial infarction (MI) were compared in 8,670 RA patients treated with TNF blockers and 2,170 patients treated with traditional DMARDs. There was no difference in the incidence of MI between the two patient groups. However, when anti-tnf responders and nonresponders were compared, the risk of MI was markedly reduced in patients exerting a good clinical response after 6 months of anti-tnf therapy in comparison to nonresponders. 40 Certainly, more epidemiological data from large cohorts are needed to determine how molecular and morphological effects of biologics translate to clinical changes of vascular morbidity and mortality.
6 Kerekes et al.: Vascular Effects of Biologics in RA 819 Conclusions Accelerated atherosclerosis and increased cardio- and cerebrovascular morbidity and mortality have been associated with RA, as well as other inflammatory rheumatic diseases. It is likely that sustained systemic inflammation and clinical activity of arthritis are major contributors to atherogenesis. Aspirin, statins, folic acid, and vitamin B12 have been introduced to the prevention and therapy of vascular diseases in RA; however, they primarily treat traditional Framingham risk factors. Corticosteroids and methotrexate may exert both beneficial and detrimental effects on the vasculature. Biological agents, primarily TNF-α inhibitors, effectively suppress arthritis and have various effects on the vascular system. Short-term administration of infliximab and possibly also etanercept and adalimumab may improve endothelial function, but in most cases this is a transient effect. There is much less data available on the effects of TNF blockers on carotid atherosclerosis and arterial stiffness. Results of the small number of studies are rather conflicting, and therefore, this issue needs further confirmation in larger cohorts. Infliximab may have a favorable short-term effect on the lipid profile, but an increasing amount of data has become available suggesting that the long-term use of infliximab may rather be proatherogenic. There are only few studies regarding influences of etanercept and adalimumab on lipids. In these studies, both anti-tnf agents had beneficial effects on dyslipidemia. Thus, different TNF blockers may have variable effects on the lipid profile, but, again, larger studies are needed to confirm this variability. Preliminary data on rituximab suggestthatitmayalsohavefavorableeffectson the lipid profile, endothelial dysfunction, and atherosclerosis. Some studies suggest that TNF blockers, primarily infliximab, may increase the number and stimulate the functions of EPCs. Thus, anti-tnf treatment may induce vasculogenesis and enhance vascular repair underlying inflammatory atherosclerosis. Finally, it is important to see how these metabolic and vascular effects translate to the clinical setting. Preliminary data from large registries indicate that anti-tnf agents may delay the first cardiovascular events and in anti-tnf responders, TNF blockade may decrease the incidence of myocardial infarction. The net effects of anti-tnf agents and other biologics on the vasculature and on vascular diseases, variability between individual agents, and differences between shortand long-term effects should be determined by more detailed analysis of patient cohorts and large registries. Due to the length of this chapter we are unable to summarize all of the cutting-edge issues that surround this research. For this reason, we recommend reading recent literature on this subject. 1,11,25,27,33,37 Acknowledgments This work was supported by research grants T (Z. S.) and a Bolyai Research Grant (P.S.). Conflicts of Interest The authors declare no conflicts of interest. References 1. Kerekes, G., Z. Szekanecz, H. Dér, et al Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35: Giles, J.T., W. Post, R.S. Blumenthal & J.M. Bathon Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2: Shoenfeld, Y., R. Gerli, A. Doria, et al Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112: Szekanecz, Z., G. Kerekes, H. Dér, et al Accelerated atherosclerosis in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1108: Ross, R Atherosclerosis an inflammatory disease. N.Engl.J.Med.340: Solomon, D.H., E.W. Karlson, E.B. Rimm, et al Cardiovascular morbidity and mortality in
7 820 Annals of the New York Academy of Sciences women diagnosed with rheumatoid arthritis. Circulation 107: Maradit-Kremers, H., C.S. Crowson, P.J. Nicola, et al Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52: Kaplan, M.J Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 18: Ohsuzu, F The roles of cytokines, inflammation and immunity in vascular diseases. J. Atheroscler. Thromb. 11: Gonzalez-Gay, M.A., M.T. Garcia-Unzueta, J.M. De Matias, et al Influence of anti-tnf-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24: Wållberg-Jonsson, S., K. Caidahl, N. Klintland, et al Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand. J. Rheumatol. 37: Soltész, P., H. Dér, G. Kerekes, et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the bracial artery and the thickness of carotid artery intima-media in patients with systemic autoimmune diseases. Clin. Rheumatol., in press. 13. Mäki-Petäjä, K.M., F.C. Hall, A.D. Booth, et al Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114: Grisar, J., D. Aletaha, C.W. Steiner, et al Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann. Rheum. Dis. 66: Paleolog, E It s all in the blood: circulating endothelial progenitor cells link synovial vascularity with cardiovascular mortality in rheumatoid arthritis? Arthritis Res. Ther. 7: Avouac, J., G. Uzan, A. Kahan, et al Endothelial progenitor cells and rheumatic disorders. Joint Bone Spine 75: Peters, M.J., D.P.M. Symmons, D.W. McCarey & M.T. Nurmohamed Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis: a EULAR task force. Arthritis Rheum. 58(9 Suppl): S Gonzalez-Juanatey, C., J. Llorca, T.R. Vazquez- Rodriguez, et al Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum. (Arthritis Care Res.) 59: Kerekes, G., P. Soltész, H. Dér, et al Effects of rituximab treatment on endothelial dysfunction and lipid profile in rheumatoid arthritis. Arthritis Rheum. 58(9 Suppl): S Hürlimann, D., A. Forster, G. Noll, et al Antitumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106: Bilsborough, W., H. Keen, A. Taylor, et al Antitumour necrosis factor-α therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 26: Gonzalez-Juanatey, C., A. Testa, A. Garcia-Castelo, et al Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum. 51: Bosello, S., A. Santoliquido, A. Zoli, et al TNF-α blockade induces a reversible but transient effect of endothelial dysfunction in patients with longstanding severe rheumatoid arthritis. Clin. Rheumatol. 27: Komai, N., Y. Morita, T. Sakuta, et al Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod. Rheumatol. 17: Gonzalez-Juanatey, C., J. Llorca, A. Sanchez- Andrade, et al. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24: Del Porto, F., B. Lagana, S. Lai, et al Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 46: Wong, M., S.P. Oakley, L. Young, et al Infliximab imporves vascular stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis Oct 17. [Epub ahead of print] 28. Van Doornum, S., G. McColl & I.P. Wicks Tumour necrosis factor antagonists improve the disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 44: Vis, M., M.T. Nurmohamed, G. Wolbink, et al Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol. 32: Seriolo, B., S. Paolino, A. Sulli, et al Effects of anti-tnf-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1069: Tam, L.S., B. Tomlinson, T.T. Chu, et al Impact of TNF inhibition on insulin resistance and
8 Kerekes et al.: Vascular Effects of Biologics in RA 821 lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26: Kiortsis, D.N., A.K. Mavridis, T.D. Filippatos, et al Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 33: Soubrier, M., P. Jouanel, S. Mathieu, et al Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 75: Saiki, O., R. Takao, Y. Naruse, et al Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J. Rheumatol. 34: Popa, C., F.H. Van Der Hoogen, T.R. Radstake, et al Modulation of lipoprotein plasma concentrations during long-term anti-tnf therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 66: Popa, C., M.G. Netea, T. Radstake, et al Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64: Garces S.P., M.J. Parreira-Santos, F.M.R. Vinagre, et al Anti-tumour necrosis factor agents and lipid profile: a class effect? Ann. Rheum. Dis. 67: Ablin, J.N., V. Boguslavski, V. Aloush, et al Effect of anti-tnfα treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79: Jacobsson, L.T., C. Turesson, A. Gülfe, et al Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32: Dixon, W.G., K.D. Watson, M. Lunt, et al Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56:
Effects of Adalimumab Treatment on Vascular Disease Associated with Early Rheumatoid Arthritis
IMAJ VOL 13 march 211 Original Articles Effects of Adalimumab Treatment on Vascular Disease Associated with Early Rheumatoid Arthritis György Kerekes MD 1, Pál Soltész MD PhD 1, Gabriella Szűcs MF PhD
More informationCoxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation
Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation Steffen Gay Arthritis linked to cardiovascular disease CV Death Osteoarthritis CHF Rheumatoid
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationRoche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
More informationRheumatoid Arteria - The Risk Factor in CV Mortality
R.J. Fasenmyer Center for Clinical Immunology Cardiovascular Disease in Inflammatory Arthritis: Getting to the Heart of the Matter Epidemiology of increased cardiovascular risk in inflammatory arthritis
More information1. Title 2. Background
1. Title EARLY PsA Effectiveness of early Adalimumab therapy in psoriatic arthritis patients from Reuma.pt, the Rheumatic Diseases Portuguese Register, Portuguese RheumatoLogy SocietY (SPR) 2. Background
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationNew Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationCurrent Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
More informationRheumatoid Arthritis - Disease, Risk Factors and Symptoms
Mædica - a Journal of Clinical Medicine EDITORIAL Metabolic Syndrome in Rheumatoid Arthritis Manole COJOCARU a ; Inimioara Mihaela COJOCARU b ; Isabela SILOSI c ; Camelia Doina VRABIE d a Titu Maiorescu
More informationAntiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study
Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study Titus F. Msoka Supervisors Marceline van Furth Yvo Smulders
More informationYour healthcare provider has ordered a Boston Heart Cardiac Risk Assessment
Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationRheumatoid arthritis: an overview. Christine Pham MD
Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching
More informationOriginal paper Reumatologia 2015; 53, 4: 200 206 DOI: 10.5114/reum.2015.53997
Original paper Reumatologia 05; 53, 4: 00 06 DOI: 0.54/reum.05.53997 Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure results of the Polish survey in
More informationArthritis Research UK Epidemiology Unit
Arthritis Research UK Epidemiology Unit Qualitative research proposal to explore factors influencing acceptable risk thresholds used to recommend particular treatment options for rheumatoid arthritis.
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationPhenotypes and Classification of Psoriasis
Rheumatology 2010 Birmingham 21 April 2010 Phenotypes and Classification of Psoriasis Christopher E.M. Griffiths Abbott Centocor Incyte Galderma Janssen-Cilag Leo Pharma Lynxx Novartis Pfizer Schering-Plough
More informationMedia Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationThe Relationship Between Rheumatoid Arthritis and Heart Failure
The Relationship Between Rheumatoid Arthritis and Heart Failure Geneva Briggs, PharmD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title.
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment
More informationOutline. Personal profile & research interests. Rheumatology research in Ireland. Current standing. Future plans
Outline Personal profile & research interests Rheumatology research in Ireland Current standing Future plans Personal profile 1983 MB Queens University 1990-3 ARUK Clinical Research Fellowship 1990-93
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationMethods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Gu NY 1, Huang XY 2, Globe D 2, Fox KM 3 1 University of Southern California,
More informationA LTCI Approach to Managing Rheumatoid Arthritis
A LTCI Approach to Managing Rheumatoid Arthritis A bit of Science, a bit of Art, a lot of Perseverance... Stephen K. Holland, MD Senior Vice President & Medical Director Long Term Care Group, Inc. Long
More informationMalattie infiammatorie croniche e coronaropatia
Malattie infiammatorie croniche e coronaropatia Enrico Natale I UO Cardiologia, Ospedale S.Camillo, Roma Factors contributing to CV disease Demographic Age Family Hx Risk factors Hypertension DM IGF/IGT
More informationRituximab for the treatment of rheumatoid arthritis
DOI: 10.3310/hta13suppl2/04 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Rituximab for the treatment of rheumatoid arthritis A Bagust, A Boland, J Hockenhull, N Fleeman, J Greenhalgh, Y Dundar,
More informationMethotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)
More informationImprovement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy
Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy R Adams 1, Ct Ng 2, A Gibbs 2, L Tilson 1, D Veale 2, B Bresnihan 2, O FitzGerald 2, M Barry 1 1. National Centre for
More informationABOUT RHEUMATOID ARTHRITIS
MEDIA BACKGROUNDER ABOUT RHEUMATOID ARTHRITIS Rheumatoid arthritis (RA) is a type of arthritis (chronic inflammatory polyarthritis) that typically affects hands and feet, although any joint in the body
More informationMaster Thesis in Medicine
RISK OF INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB IN CLINICAL PRACTICE Master Thesis in Medicine Joyce Åkerlund Supervisor: Catharina Lindholm, MD, PhD, Associate Professor Department
More informationInfluence of Body Mass Index in Response to Biologic therapy in Rheumatoid Arthritis
Influence of Body Mass Index in Response to Biologic therapy in Rheumatoid Arthritis Introduction Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects both joints and extraarticular
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More informationDr Sarah Levy Consultant Rheumatology Croydon University Hospital
Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Contents Definition/ epidemiology Diagnosis Importance of early diagnosis/ treatment Guidelines Evidence based treatment protocol Current
More informationGP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
Psoriasis : It s not just skin de eep NICE Guidelines and Quality Standards: a collaboration to deliver quality care GP Symposium Dermatology y p gy Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
More informationLDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts.
LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts Introduction While both small and large LDL particles may be atherogenic,
More informationClinically Actionable Biomarkers in Rheumatoid Arthritis
Clinically Actionable Biomarkers in Rheumatoid Arthritis PepTalk January 6, 2009 William Robinson, MD, PhD Stanford University School of Medicine VA Palo Alto Health Care System T cell mediated Autoimmune
More informationSubject Index. Bariatric surgery, obesity management 134
Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationEffect of Methotrexate on Serum Levels of IL-1α and IL-8 in Rheumatoid Arthritis
THE RHEUMATOID IRAQI POSTGRADUATE ARTHRITIS MEDICAL JOURNAL VOL.12, NO. 3,2013 Effect of Methotrexate on Serum Levels of IL-1α and IL-8 in Rheumatoid Arthritis Ahmed A. Al-Hassan*, Mohammed O. Hamzah**,
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationEffectiveness and Drug Adherence in Rheumatoid Arthritis Patients on Biologic Monotherapy: A prospective observational study in Southern Sweden
Effectiveness and Drug Adherence in Rheumatoid Arthritis Patients on Biologic Monotherapy: A prospective observational study in Southern Sweden Collaborators: Primary investigators Dr Lars Erik Kristensen,
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationHow will we prevent rheumatoid arthritis? Kevin Deane, MD/PhD Division of Rheumatology University of Colorado
How will we prevent rheumatoid arthritis? Kevin Deane, MD/PhD Division of Rheumatology University of Colorado Outline 1) Brief overview of natural history of RA and how current understanding of disease
More informationMultiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden
Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS
More informationCan Rheumatoid Arthritis treatment ever be stopped?
Can Rheumatoid Arthritis treatment ever be stopped? Robert L. DiGiovanni, DO, FACOI Program Director Largo Medical Center Rheumatology Fellowship robdsimc@tampabay.rr.com Do not pour strange medicines
More informationTreatment of Rheumatoid Arthritis in the New Millennium. Neal I. Shparago, D.O., FACP, FACR
Treatment of Rheumatoid Arthritis in the New Millennium Neal I. Shparago, D.O., FACP, FACR What is RA? Symmetric inflammatory polyarthritis Rheumatoid factor positive in 80% Anti-CCP positive in approximately
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationResearch Article Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham Risk Score
Scientifica Volume 2013, Article ID 371569, 4 pages http://dx.doi.org/10.1155/2013/371569 Research Article Cardiovascular Risk in Psoriasis: A Population-Based Analysis with Assessment of the Framingham
More informationADDRESSING CARDIOVASCULAR RISK FACTORS AND THERAPY EFFECTS IN RHEUMATOID ARTHRITIS: IMPLICATIONS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
From the RHEUMATOLOGY UNIT, DEPARTMENT OF MEDICINE, KAROLINSKA UNIVERSITY HOSPITAL HUDDINGE, KAROLINSKA INSTITUTET, STOCKHOLM, SWEDEN ADDRESSING CARDIOVASCULAR RISK FACTORS AND THERAPY EFFECTS IN RHEUMATOID
More informationRheumatoid Arthritis www.arthritis.org.nz
Rheumatoid Arthritis www.arthritis.org.nz Did you know? Rheumatoid arthritis (RA) is the third most common form of arthritis Approximately 40,000 New Zealanders have RA RA can occur at any age, but most
More informationTreatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Complete Summary GUIDELINE TITLE (1)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
More informationPsoriasis and Vascular Disease: An Unsolved Mystery
REVIEW Psoriasis and Vascular Disease: An Unsolved Mystery Michael L. Shelling, BS, a Daniel G. Federman, MD, c Srdjan Prodanovich, MD, a Robert S. Kirsner, MD, PhD a,b a Department of Dermatology and
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationMen Sexual Dysfunction Associated with Obesity and Metabolic Syndrome
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationDISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY
ORIGINAL ARTICLES DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY Teodora Serban 1,2, Iulia Satulu 2, Oana Vutcanu 2, Mihaela Milicescu 1,2, Carina Mihai 1,2, Mihai Bojinca 1,2, Victor
More informationTreating Rheumatoid Arthritis to Target : the patient version of the international recommendations
Treating Rheumatoid Arthritis to Target : the patient version of the international recommendations Data presented from the publication: M. de Wit, et al. Ann Rheum Dis. 2011;70:891-5. Epub Apr 7, 2011.
More informationDesign and principal results
International Task Force for Prevention Of Coronary Heart Disease Coronary heart disease and stroke: Risk factors and global risk Slide Kit 1 (Prospective Cardiovascular Münster Heart Study) Design and
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationRobert Krysiak, Anna Gdula-Dymek, Bogus³aw Okopieñ
Pharmacological Reports 2013, 65, 429 434 ISSN 1734-1140 Copyright 2013 by Institute of Pharmacology Polish Academy of Sciences Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory
More informationSOLUBLE TUMOR-ASSOCIATED ANTIGENS AND SECONDARY MALIGNANCIES IN AUTOIMMUNE- RHEUMATOID DISEASES
SOLUBLE TUMOR-ASSOCIATED ANTIGENS AND SECONDARY MALIGNANCIES IN AUTOIMMUNE- RHEUMATOID DISEASES ÉVA SZEKANECZ, MD Tutors: Emese Kiss MD, associate professor Gabriella Szőcs MD, assistant professor UNIVERSITY
More informationRheumatoid arthritis: diagnosis, treatment and prognosis. Dr David D Cruz MD FRCP Consultant Rheumatologist
Rheumatoid arthritis: diagnosis, treatment and prognosis Dr David D Cruz MD FRCP Consultant Rheumatologist The Louise Coote Lupus Unit St Thomas Hospital London AMUS meeting London 7 th March 2012 Disclosures
More informationLinking biobanks to registries: Why and how? Anne Barton
Linking biobanks to registries: Why and how? Anne Barton Biobanks why should we collect samples? Anti-TNF treatment in RA Cost approx. 8,000/person/year 30-40% RA patients do not respond Rare, serious
More informationCan Common Blood Pressure Medications Cause Diabetes?
Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationThe management of rheumatoid arthritis
Medical management of rheumatoid arthritis Peter Jones Correspondence to: peter.jones@qehealth.co.nz The management of rheumatoid arthritis has changed in the last 10 years. Back then, a patient who awoke
More informationRisk Factors for Fire Fighter Cardiovascular Disease
Risk Factors for Fire Fighter Cardiovascular Disease EXECUTIVE SUMMARY Prepared by: Jefferey L. Burgess, MD, MS, MPH Mel and Enid Zuckerman College of Public Health The University of Arizona The Fire Protection
More informationEndothelial Function and Inflammatory Activity in Patients with Recent Onset of Severe Plaque Psoriasis
64 The Open Dermatology Journal, 2008, 2, 64-68 Open Access Endothelial Function and Inflammatory Activity in Patients with Recent Onset of Severe Plaque Psoriasis Lotus Mallbris *,a, John Pernow b and
More informationUnmet Needs in RA: The Role of Anti-TNF Therapy
A SUPPLEMENT TO Rheumatology News Unmet Needs in RA: The Role of Anti-TNF Therapy Therapeutic Issues in RA Clinical Practice Roy Fleischmann, MD (Chair) Clinical Professor of Medicine University of Texas
More informationPsoriatic Arthritis www.arthritis.org.nz
Psoriatic Arthritis www.arthritis.org.nz Did you know? Arthritis affects one in six New Zealanders over the age of 15 years. Psoriatic arthritis usually appears in people between the ages of 30 to 50.
More informationSpeaking Plainly. Biologic treatment options for rheumatoid arthritis
in association with Plain English Campaign Speaking Plainly Biologic treatment options for rheumatoid arthritis A guide to help healthcare professionals talking to patients with rheumatoid arthritis Foreword
More informationRheumatoid Arthritis
Rheumatoid Arthritis Carole Callaghan Principal Pharmacist NHS Lothian Aim To update pharmacists on the current management of rheumatoid arthritis and explore ways to implement pharmaceutical care for
More informationEarly Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis
Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis 奇 美 醫 院 過 敏 免 疫 風 濕 科 陳 宏 安 Rheumatoid arthritis Most common chronic inflammatory joint disease Multisystem autoimmune disease of unknown
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationANTIBODIES AGAINST CITRULLINATED PEPTIDES IN EARLY RHEUMATOID ARTHRITIS: DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE
ANTIBODIES AGAINST CITRULLINATED PEPTIDES IN EARLY RHEUMATOID ARTHRITIS: DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE Principal investigators: Dr Raimon Sanmartí Sala Hospital Clínic i Provincial de Barcelona
More informationIn the last decade, there have been major changes in the
233 Promising New Treatments for Rheumatoid Arthritis The Kinase Inhibitors Yusuf Yazici, M.D., and Alexandra L. Regens, B.A. Abstract Three major advances over the last decade have impacted the way we
More informationRecognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis
White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,
More informationDoes Rheumatoid Arthritis Equal Diabetes Mellitus as an Independent Risk Factor for Cardiovascular Disease? A Prospective Study
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 61, No. 11, November 15, 2009, pp 1571 1579 DOI 10.1002/art.24836 2009, American College of Rheumatology ORIGINAL ARTICLE Does Rheumatoid Arthritis
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationHYPERCHOLESTEROLAEMIA STATIN AND BEYOND
HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause
More informationRheumatoid Arthritis. Disease RA Final.indd 2 15. 6. 10. 11:23
Rheumatoid Arthritis Disease RA Final.indd 2 15. 6. 10. 11:23 Understanding what to expect can help you prepare for your transition into treatment. Rheumatoid Arthritis What You Need To Know About Rheumatoid
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationBIOM 255 - Firestein, Winter 2009. Rheumatoid arthritis. Page 1
Rheumatoid arthritis Page 1 Vascular events in RA Synovium in rheumatoid arthritis Non-extra articular RA Extra articular RA Turesson, et al. Ann Rheum Dis. 2007;66:60 Normal Rheumatoid Arthritis Major
More informationRheumatoid Arthritis and Treat-to-Target
Rheumatoid Arthritis and Treat-to-Target A Case of Need Encountering Opportunity Need RA affects approximately 1.5 million adults in the United States 1 20%-30% face permanent work disability if not treated
More informationVitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model
Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC
More information